Glenn Bolduc, President and CEO of Implant Sciences, an up and coming technology leader in the homeland security space, talks about his company, products, and vision for the future. www.implantsciences.com Ticker: IMSC

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014.

“While there may be monthly variations, we are seeing a general trend of rapidly increasing enrollment through the support of our new CROs, Ergomed and Aptiv Solutions, the addition of new centers, and a definite increase in interest by investigators in enrolling patients in our study. As we continue to expand the study to more centers in more countries, we expect to see continued increase in the rate of enrollment in this Phase III trial,” stated CEL-SCI Chief Executive Officer Geert Kersten.

So far, a total of 197 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine

Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-lable, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer.

“Patients and doctors alike are increasingly aware of the potential promise of immunotherapy in the fight against cancer. Approximately 200 patients are already enrolled in this Phase III study with Multikine and our goal is to have a total of 880 patients enrolled worldwide by the end of 2015,” stated CEL-SCI Chief Executive Officer Geert Kersten.

Further expansion of the trial is underway with a goal to have a total of about 100 clinical centers through 20 countries by the end of 2015.

About Multikine Phase III Study

The Multikine Phase III study (the IT-MATTERS Study) is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine

Multikine (Leukocyte Interleukin, Injection) is an immunotherapeutic agent that is being tested in a randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use by the US FDA or other Regulatory agencies following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

EVEN YEHUDA, Israel, June 2, 2014 /PRNewswire/ —

Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), a clean energy company that develops, manages and owns waste-to-energy projects, announced today that Mecklenburg County has issued the Company an air emissions permit for its 5.2 MW waste-to-energy project in Charlotte, North Carolina. Obtaining the air emissions permit is a requirement prior to build-out and operations at the plant. The permit signifies that the 5.2 MW waste-to-energy plant meets stringent local, regional and national environmental emissions regulations.

“This marks another milestone in the development of our 5.2 MW clean energy project in Charlotte. The air permit usually tends to be one of the more difficult-to-get permits. We are now preparing to submit applications for the remaining permits, but the biggest piece of the permitting process is now behind us,” stated Bluesphere CEO Shlomi Palas. “We are nearing ground-breaking on the site and will produce and deliver power on schedule.”

Bluesphere is the project owner, developer and manager for this 5.2 MW organics-to-energy anaerobic digester. The facility will intake organic waste such as food and farm waste that would normally go into landfills. The organic waste is processed in an anaerobic digester to emit biogas, which then is turned into electricity and compost is a by-product. The facility generates revenues from intake of organic waste, as well as the sale of clean, renewable electricity, and the sale of compost.

A Fortune 50 company has signed on to provide over $14 million in debt project financing for the facility and a leading environmental finance fund will provide equity project financing of $8.0 million, with an additional $1.5 million to be kept in reserve. One of the largest power holding companies in the U.S. has signed a long-term contract with Bluesphere to purchase electricity generated at the Charlotte plant. Compost, which is a by-product of the organics-to-energy generation process, will be purchased under a contractual agreement by one of the largest privately held composting companies in the world.

Bluesphere is developing its second U.S. organics-to-waste facility in Rhode Island and by 2018 the Company plans to have 11 facilities built with 6 more under construction and development.

Waste-to-energy is one of the fastest growing segments in the renewable energy markets. According to SBI Energy, the thermal and biological segments reached $6 billion in 2012 and will reach $29 billion by 2022.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced that the University of Cincinnati Cancer Institute is the latest medical center in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). CEL-SCI’s study is already active in dozens of clinical centers in 12 countries and is expected to expand to a total of 20 countries with an estimated 880 patients to be enrolled by the end of 2015. According to the American Society of Clinical Oncology, head and neck cancers account for about 3% to 5% of all cancers in the United States.

The University of Cincinnati’s Comprehensive Head and Neck Cancer Center offers patient-centered care from a multidisciplinary team that focuses exclusively on treating cancers of the head and neck. This includes cancers of the oral cavity (tongue, jaw, lip, cheek, and hard palate), throat (tonsil, and base of tongue), larynx (voice box), nose and sinus cavity, skull base, salivary glands, thyroid gland and parathyroid gland. The clinical team includes head and neck cancer surgeons, radiation oncologists, medical oncologists, head and neck radiologists, pathologists, speech therapists and experienced head and neck cancer nurses.

Dr. Keith Casper, Co-Director of the Comprehensive Head and Neck Cancer Center, is the Principal Investigator of CEL-SCI’s Phase III trial at the University of Cincinnati. Dr. Casper has been a Head and Neck Surgical Oncologist at UC Health since 2009. He is also an Assistant Professor of Otolaryngology- Head and Neck Surgery at the University of Cincinnati College of Medicine.

“The University of Cincinnati Cancer Institute’s Comprehensive Head and Neck Cancer Center is one of the largest centers in its region specialized in head and neck cancer. Dr. Casper is a renowned expert and thought leader in head and neck cancer and we are very pleased to have his participation in our global study,” stated CEL-SCI Chief Executive Officer Geert Kersten.

To read the entire article please visit the following link: http://www.energycentral.com/enduse/energyefficiency/articles/2913/Fast-Food-Industry-Can-Become-Fastest-Growing-Player-in-Clean-Energy

When you think of NYC “street meat” it conjures up images of cold hotdogs and greasy kabobs; but in recent years these curb-side vendors have gone gourmet, with chefs from some of the finest of NYC eateries taking their show on the road. Nowadays, you can get everything from lobster to creme brûlée from the side of a truck. So if you are willing to skip the wait-staff and ditch the silverware you might want to get your grub to-go. But in true Urban Guidebook style we aren’t making you wander the streets alone, we’ve made our top five picks for the best fried, frozen, and frosted food trucks NYC has to offer and our host, Annamaria Chen, is sampling some our staff picks all for you.

Our Food Truck Picks:
– Waffles and Dinges
– Korilla BBQ
– Carpe Donut
– Mac Truck
– Sprinkles ATM

Corporate Profile is a content provider for the ClearVISION & ConnectiMED Networks.

This episode is currently streaming on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

Pompano Beach, Fla., May 21, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc.(DSKX), a leading developer of personal care products and specialty pharmaceuticals, today announced it has appointed Dr. Brijeshkumar Patel, PhD to the newly created position of Director of Research and Development. In this role Dr. Patel will focus on the development of transdermal drug delivery systems for the Company’s hair-care products, as well as restructuring existing and new molecules for increased absorption and effectiveness. He will work alongside a team of chemists both within DS Healthcare and with the Company’s external consultants to develop skin-care applications. In addition to maintaining the highest quality controls for the Company’s over-the-counter formulations, Dr. Patel will also collaborate with Aptiv Solutions, DS Healthcare’s clinical research organization (CRO) on the Company’s prescription-grade hair formulation currently under development.

“We are executing on the pursuit of science that enhances hair regrowth and youthful skin. Dr. Patel joins us as Director of R&D to lead our clinical development efforts for both our prescription hair loss development program and our portfolio of over-the-counter hair care and skin care products,” stated DS Healthcare President and CEO Daniel Khesin. “We’ve seen demand for our over-the-counter products continue to grow based on the performance of our proprietary, patent-pending formulations. With Dr. Patel on our team, we believe we will be in a position to accelerate our innovation and clinical programs with a goal towards expanding our intellectual property, product portfolio and corresponding revenues.”

Dr. Patel has over 7 years of research experience in developing novel drug delivery systems for pulmonary, oral and topical delivery of small molecules and peptide drugs. He brings to DS Healthcare specific expertise in designing preclinical and clinical study protocols. He has authored 10 articles published in peer-reviewed scientific publications and delivered over a dozen poster and oral presentations at scientific conferences. Dr. Patel received his Ph.D. in Pharmaceutical Sciences from the Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center. He also earned his M.S. in Pharmaceutical Sciences from the School of Pharmacy, Campbell University, and his B.S. in Pharmaceutical Sciences from the Shri B M Shah College of Pharmaceutical Education and Research, HNGU, India.

DS Healthcare Group recently announced its intention to file an Investigational New Drug application with the U.S. Food and Drug Administration for a topical hair loss treatment. If approved, it would be the third FDA-approved treatment for hair loss and only the second topical treatment. The Company has recently filed two patents for its prescription and over-the-counter hair loss formulations.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group’s flagship brand, visit www.dslaboratories.com

HAIFA, Israel, May 20, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the latest advancement in its clinical and commercial development programs in South Korea. The South Korean Ministry of Food and Drug Safety (MFDS) has recently cleared Pluristem’s upgraded manufacturing process in its new facility in Haifa, Israel. The cells produced at Pluristem new facility will be used by Korean sites joining the large Phase II study currently conducted by Pluristem in intermittent claudication (IC) patients. This Phase II IC study is currently ongoing in the U.S., Israel and Germany.

“South Korea is a large market in which we are very well positioned due to our strategic partnership agreement with CHA Bio & Diostech. We believe that our PLX cells are the only allogeneic cellular therapy product approved for clinical trials in South Korea. With the MFDS’s clearance for our cell manufacturing processes, we are now pleased to move forward with our Phase II IC trial in Korea,” stated Pluristem Chairman and CEO Zami Aberman.

Mr. Aberman will present at BIO KOREA 2014, which will take place in Goyang, South Korea on May 28th through May 30th. His presentation titled, “Cell Therapy – From the Bench to Multi-National Clinical Studies,” will take place during the “Stem Cell & Regenerative Medicine” track on May 29th at 2:50 pm. During the presentation, Mr. Aberman will discuss the collaborative clinical and commercial development process jointly undertaken by Pluristem and CHA.

Pluristem is operating in the South Korean market through an exclusive out-license and strategic partnership agreement with CHA Bio & Diostech (Kosdaq:CHA) for the use of its Pluristem’s PLacental eXpanded (PLX) cells for peripheral artery disease (PAD), in South Korea. Under the terms of the agreement, CHA will perform and fund multiple clinical trials in South Korea using Pluristem proprietary PLX cells. Upon the first regulatory approval for a PLX product in South Korea, Pluristem and CHA will establish a joint venture (JV) co-owned by the parties.

According to market research firm Clearstate, 1 million people in South Korea suffer from PAD and the growth forecast for the number of people diagnosed and treated in the country is moderate-to-high.

WOODLAND HILLS, Calif.–(BUSINESS WIRE)–

Vertical interest social media network, CrowdGather, Inc. (CRWG), today announced that it has closed its Merger Agreement with Plaor, Inc. Pursuant to the Merger, the shareholders of Plaor received 55,075,800 shares of common stock of CrowdGather. After the completion of the merger, CrowdGather will have a total of 116,733,508 shares of common stock issued and outstanding. Additionally the company has appointed Hazim Ansari to the Company’s Board of Directors.

In his 16 years as an intellectual property attorney, Hazim has assisted dozens of emerging companies in raising financing, establishing critical joint ventures, and closing foundational revenue deals. Hazim has co-founded several companies, including Novel IP which is a pioneer in offshore IP industry and Plaor which recently merged with CrowdGather, and successfully built them through to profitability and/or acquisitions. Hazim received his B.S. in Chemical Engineering from Stanford University and his J.D. from Loyola Law School (magna cum laude).

“We believe this merger positions our company to capitalize on much higher growth opportunities in gaming and mobile applications,” said CrowdGather’s Chairman and CEO, Sanjay Sabnani. “Additionally, we are excited to have someone of Hazim’s experience join our team. His expertise as an entrepreneur along with his extensive transactional experience makes him a perfect addition and complement to our team as we seek to grow our catalog of games and apps.”

“I am excited by CrowdGather’s vision for the social gaming industry. The company is building a business that takes advantage of the growth opportunities in social gaming while accounting for, and leveraging, the financial realities of the market”, said Hazim Ansari. “I look forward to helping scale its gaming asset acquisition efforts.”